The field of semisynthetic cannabinoids represents a dynamically growing group of psychoactive substances. A major concern lies in the continuous chemical modification of their structures to avoid legal regulation. The pharmacological and toxicological properties of new derivatives of THC, HHC, and CBD remain largely unexplored. Laboratory analyses of commercially available HHC products have revealed discrepancies between the declared and actual content. In addition, insufficient labeling on the packaging has been identified as an immediate public health risk, as users are unaware of the doses they are consuming. Based on the rapid development of (not only) semisynthetic cannabinoids, the authors propose initiating a serious discussion on the introduction of a generic or hybrid regulatory system, inspired by models adopted in several European countries.